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Introduction: Goal-directed therapy (GDT) has been shown in numerous studies to decrease perioperative
morbidity and mortality. The mechanism of benefit of GDT, however, has not been clearly elucidated. Targeted
resuscitation of the vascular endothelium with GDT might alter the postoperative inflammatory response and be
responsible for the decreased complications with this therapy.
Methods: This trial was registered at ClinicalTrials.gov as NCT01681251. Forty patients undergoing elective open
repair of their abdominal aortic aneurysm, 18 years of age and older, were randomized to an interventional arm
with GDT targeting stroke volume variation with an arterial pulse contour cardiac output monitor, or control, where
fluid therapy was administered at the discretion of the attending anesthesiologist. We measured levels of several
inflammatory cytokines (C-reactive protein, Pentraxin 3, suppressor of tumorgenicity–2, interleukin-1 receptor
antagonist, and tumor necrosis factor receptor-III) preoperatively and at several postoperative time points to
determine if there was a difference in inflammatory response. We also assessed each group for a composite
of postoperative complications.
Results: Twenty patients were randomized to GDT and twenty were randomized to control. Length of stay was not
different between groups. Intervention patients received less crystalloid and more colloid. At the end of the study,
intervention patients had a higher cardiac index (3.4 ± 0.5 vs. 2.5 ± 0.7 l/minute per m2, p < 0.01) and stroke volume
index (50.1 ± 7.4 vs. 38.1 ± 9.8 ml/m2, p < 0.01) than controls. There were significantly fewer complications in the
intervention than control group (28 vs. 12, p = 0.02). The length of hospital and ICU stay did not differ between
groups. There was no difference in the levels of inflammatory cytokines between groups.
Conclusions: Despite being associated with fewer complications and improved hemodynamics, there was no
difference in the inflammatory response of patients treated with GDT. This suggests that the clinical benefit of GDT
occurs in spite of a similar inflammatory burden. Further work needs to be performed to delineate the mechanism
of benefit of GDT.
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The delivery of intravenous fluids to surgical patients is
one of the most important aspects in the delivery of
anesthetic care and has undergone several paradigm
shifts over the past 60 years [1–4]. The goal-directed
therapy (GDT) method of fluid administration relies on
the utilization of minimally invasive cardiac output
monitoring to tailor fluid administration to a maximal
cardiac output or other reliable markers of preload
such as stroke volume variation (SVV) or pulse pressure
variation (PPV) [5]. In aggregate, the studies performed to
date, predominantly in patients undergoing gastrointes-
tinal surgery, have demonstrated that the utilization of
GDT decreases morbidity, mortality and both hospital
and ICU length of stay [6–11]. The benefit of GDT in vas-
cular surgery patients has been less robust, presumably
due to the higher rate of cardiovascular complications in
this patient population [12, 13]. The mechanism of benefit
of GDT, however, has been examined in only a few studies
[9, 14–16]. There has been a suggestion by some that GDT
reduces gut mucosal hypoperfusion and this may result in a
less robust inflammatory response to surgery [17, 18].
It is possible that the benefit of GDT results from
improved resuscitation of the endothelium, which in turn
could be associated with decreases in the inflammatory
response seen after surgery. This improved endothelial
resuscitation may be associated with decreased vascu-
lar permeability resulting in less tissue edema and less
tissue hypoxia which may lead to decreased postoperative
organ dysfunction [19].
We hypothesized that the increase in cardiac index
(CI) and decrease in postoperative complications that
has been demonstrated in previous trials of GDT would
be associated with decreases in inflammatory biomarkers.
To that end we designed a trial to determine if GDT is
associated with lower levels of inflammatory biomarkers.
In this study, we randomized 40 patients presenting
for elective open repair of abdominal aortic aneurysms
(AAA) to receive fluid administration based on either a
GDT approach or a control method (fluid administered
based on static preload parameters and traditional
hemodynamics) and measured the levels several pro-
and anti-inflammatory cytokines in the perioperative
period. We also assessed each group for a composite of
postoperative complications. Our hypothesis was that
patients in the GDT group would have fewer postoperative
complications and lower levels of inflammatory biomarkers
in the postoperative period.
Methods
This trial was registered at ClinicalTrials.gov as
NCT01681251. After approval from the University of
Manitoba Research Ethics Board, we approached all
patients over the age of 18 years presenting for electiveopen repair of their AAA. Written, informed consent was
obtained from all patients. Patients were excluded
from the trial if they had any of the following: age
over 80 years, weight greater than 120 kg, known or
suspected aortic insufficiency, renal dysfunction
(serum creatinine >150 μmol/l), active congestive
heart failure, or atrial fibrillation. The weight, aortic
insufficiency and atrial fibrillation exclusion criteria
were included as the minimally invasive cardiac output
monitor we used (FloTrac Vigeleo system; Edwards
LifeSciences, Irvine, CA, USA) was inaccurate in these
conditions. Patients with pre-existing renal dysfunction
were excluded as they might have adverse renal outcomes
from the colloid therapy utilized in our GDT protocol.
Patients were randomized to either the intervention or
control group by way of a sealed envelope. Anesthetic
technique was at the discretion of the attending
anesthesiologist, and at our institution consists of
general anesthesia, with the placement of a thoracic
epidural catheter prior to induction for postoperative anal-
gesia. The only difference in anesthetic technique between
the two groups was with respect to fluid administration
(see below). Standard Canadian Anesthesiologists Society
monitors with the addition of an arterial line, and central
venous access with an 8.5 Fr cordis were placed in all
patients. In addition, the FloTrac/Vigeleo minimally inva-
sive cardiac output monitor was utilized in all patients.
Patients were mechanically ventilated with 8 cm3/kg tidal
volume based on ideal body weight (IBW) with respiratory
rate adjusted to achieve an end-tidal CO2 level of 35–
40 mmHg. Positive end-expiratory pressure was set at 5
cmH2O. Fraction of inspired O2 was titrated to maintain
an oxygen saturation of >95 %. These specific ventilator
settings were utilized to improve the accuracy of SVV de-
termination, which was our trigger for fluid administration.
In the intervention group, patients received a background
crystalloid infusion of 3 cm3/kg IBW of lactated
Ringers solution. In the intervention group, if the
SVV became greater than 13 %, 250 ml 130/0.4
hydroxyethyl starch (HES) solution (Voluven, Fresenius
Kabi, Bad Homburg, Germany) was administered, and
repeated until the SVV became less than 13 %. This
was done up to a maximum of 55 cm3/kg 130/0.4
HES, and at this point further bolus fluid was chan-
ged to lactated Ringers. Of note, no patients reached
this maximum limit of colloid. If the SVV was less
than 13 % and CI was less than 2.2 l/minute per m2
inotropic therapy was started (typically norepinephrine). If
SVV was less than 13 % and CI was >2.2 l/minute per m2
and mean arterial pressure (MAP) was less than 60 mmHg,
phenylephrine by infusion was administered. Prior to
aortic cross clamp removal in the intervention group, the
attending anesthesiologist was allowed to administer
a fluid bolus even if the SVV was <13 % in order to
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clamp removal.
Anesthesiologists treating patients in the control
group did not have the CI or SVV information available
to them from the FloTrac sensor. This information was
covered on the monitor by way of an opaque index card.
Control group patients had fluid administered to them
at the discretion of the attending anesthesiologist, with
the only stipulation being that colloid administration
would be exclusively Voluven. Our institution has no
protocol for GDT, and fluid in these patients is typically
administered based on static preload variables (i.e., central
venous pressure (CVP)) or low MAP.
Postoperative fluid administration and hemodynamic
support was not protocolized and was at the discretion of
the attending surgeon. This typically involved a baseline
crystalloid infusion based on body weight, with a gradual
transition to enteral nutrition at the surgeon’s discretion.
Autologous blood was collected and returned to the
patient via cell saver, and allogenic blood was administered
if there was no cell saver blood available and hemoglobin
was less than 90 g/l. The transfusion of platelets, plasma
and other coagulation factors was at the discretion of the
attending anesthesiologists.
Intra-operative hemodynamic data (including heart rate,
MAP, cardiac output, CI, SVV, CVP, and end-tidal CO2)
were collected at 60 Hz by TrendFace Solo software
(iExcellence, Wildau, Germany). The per-second values
were meaned to obtain data for every minute of the
case, performed off-line using Microsoft Excel (Redmond,
WA, USA). Intra-operative data collected included opera-
tive duration, aortic cross clamp time, fluid administration
(crystalloid, colloid, blood products), and fluid losses (blood
and urine output).
Blood samples were analyzed preoperatively (baseline),
immediately postoperatively, 6 hours postoperatively and
24 hours postoperatively by enzyme-linked immunosorbent
assay (ELISA) for the following biomarkers associated
with inflammation: interleukin (IL)-10, IL-6, Pentraxin-3
(PTX3), C-reactive protein (CRP), suppressor of tumorgeni-
city (ST)-2, macrophage chemotactic protein 1 (MCP-1/
CCL2), IL-1-receptor antagonist (IL-1Ra), and soluble
tumor necrosis factor receptor II (sTNFR-II).
Cytokines were analyzed by the following method.
Analyte levels in cryopreserved serum were determined
using MesoScale Discovery (MSD, Gaithersburg, MD,
USA) electrochemiluminescence detection to quantify
binding events on patterned arrays using minor modifica-
tions of the manufacturer’s protocol. To provide uniform-
ity in comparing data between different lots, constant
internal lab standards (purchased from Peprotech, Rocky
Hill, NJ, USA, and R and D Systems, Minneapolis, MN
USA) were established and used throughout the
study. Briefly, samples and standards were incubatedon singleplex MSD plates for 3 hours (instead of 2 hours)
and the plate incubated with detection antibody for
3 hours (instead of 2 hours) before wash. All other steps
were as per manufacturer’s recommendations. Analysis
was on a SECTOR™ 2400 instrument (MSD). The operator
was blind to the nature of all samples during processing,
with subsequent statistical analysis also performed inde-
pendently. Interassay variation was generally 4–10 %.
There were not always sufficient samples obtained for
each individual to be quantified for each analyte at each
time point. Assays for which MSD plates were not avail-
able were performed by ultrasensitive ELISA as described
previously [20, 21]. Briefly, titrations of four two-fold dilu-
tions of each serum were assessed with reagents from Bio-
Legend (San Diego, CA, USA) as described. Inter-assay
ELISA variability was generally <10 %.
A blinded assessor determined postoperative complica-
tions. These included myocardial infarction, pneumonia,
sepsis and septic shock, acute kidney injury, supra-
ventricular dysrhythmia, ischemic gut, or ICU admission.
All complications were adjudicated based on standard
criteria [22–25].
Statistical analysis
Based on patient data from open repair of AAA at our
institution, average length of stay (LOS) for this procedure
was 7 ± 3 days. We hypothesized that patients undergoing
GDT at our institution could expect a 20 % decrease in
their LOS. With an α level of 0.05 and a β of 0.8, we
calculated our total sample size to be 40 patients. We
chose LOS to power our study, as we did not know the
inflammatory biomarker levels that may result from this
surgery, nor what difference to expect in the intervention
and control groups based on our intervention.
Statistical analysis was performed using GraphPad Prism
version 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
Categorical variables were analyzed with the Fisher’s exact
test. Between-group continuous variables were analyzed
with a student’s t-test. The Kolmorgov-Smirnov test was
performed to assess for normality. Cytokine responses were
analyzed between groups utilizing repeated measures ana-
lysis of variance. Results are expressed as mean ± SD, and
results were considered statistically significant if p <
0.05.
Results
Baseline demographic and laboratory data are presented
in Table 1. Patients in the control group were of similar
age to those in the intervention group (67.9 ± 8.9 years
vs. 70.6 ± 9.8 years, p = 0.368). There were 15 males in the
control group and 12 in the intervention group (p = 0.31).
Medical co-morbidities including diabetes, hypertension,
hyperlipidemia, and ischemic heart disease were also simi-
lar between groups. The number of patients who had a





Gender (male to female) 15:5 12:8
Age (years) 67 ± 8 70 ± 9






Ischemic heart disease 8 8
Myocardial infarction 7 8
CABG 2 3
Stent 3 3
Ejection fraction (%) 55 ± 7 53 ± 11
Hemoglobin (g/l) 143 ± 15 134 ± 16
Creatinine (mmol/l) 87 ± 27 100 ± 34
eGFR (ml/minute) 83 ± 32 69 ± 29
P-POSSUM
Morbidity rate (%) 63 ± 20 63 ± 22
Mortality rate (%) 8 ± 8 9 ± 10
Values are shown as n, unless otherwise indicated. COPD chronic obstructive
pulmonary disease. CABG coronary artery bypass grafting, eGFR estimated
glomerular filtration rate (Cockroft-Gault formula), P-POSSUM Portsmouth
Physiologic and Operative Severity Score for the enUmeration of Mortality
and Morbidity
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grafting or coronary stent placement was also similar
between groups. As such, the morbidity score of the
Portsmouth Physiologic and Operative Severity Score for
the enUmeration of Mortality and Morbidity (P-POSSUM)
scores were similar between groups (63.4 ± 20.6 vs.
63.8 ± 22.8, p = 0.95).
Despite being powered for a reduction in hospital
LOS, there was no difference between intervention and
control groups in this parameter (8 (6–12) vs. 8 (7–13)
days; p = 0.73).
There were no baseline differences between groups in
the traditional hemodynamic parameters of heart rate,
MAP, and CVP (Table 3). Cardiac index (2.5 ± 0.4 vs
2.5 ± 0.7 l/minute per m2, p = 0.94) and stroke volume
index (43.8 ± 8.7 vs. 38.1 ± 9.8 ml/m2, p = 0.29) at baseline
were also similar between the control and intervention
groups, respectively.
Surgical duration and aortic cross clamp times were
similar between groups 228 (210-243) vs. 210 (174-246)
minutes for surgical duration, and 50 (38-69) vs. 52
(40-64) minutes for aortic cross clamp time for control
and intervention groups, respectively; see Table 2). There
was a trend towards more vasopressor administration inthe intervention group (19 vs. 15 patients, p = 0.08; Fish-
er’s exact test; Table 2). Estimated blood loss, cell saver
blood loss and intraoperative urine output were also simi-
lar between groups (Table 2).
With respect to fluid administration, there was
more crystalloid administration in the control versus
intervention group (Table 2). The patients in the
intervention group received more colloid (both on an
ml and ml/kg basis) than those in the control group
(3.5 ± 1.5 vs. 2.0 ± 1.3 ml/kg, p < 0.01).
With the increased colloid administration, the patients
in the intervention group at the end of the study had
significantly higher CI and stroke volume index (SVI)
(Table 3). The SVV was also significantly lower in the
intervention group. The MAP, heart rate and CVP were
all similar between groups at the end of the study.
In the postoperative period (postoperative days 1–7)
there was no difference between groups with respect to
crystalloid or colloid administration, or red blood cell trans-
fusion. On average, patients tolerated their first enteral diet
and full diet on the same postoperative day.
The composite outcome of perioperative complications
occurred more frequently in the control group than the
intervention group, and this was statistically significant
(28 vs. 12, p = 0.02, Fisher’s exact test; Table 4).
All of the biomarkers measured demonstrated a statis-
tically significant increase in levels from baseline to the
24-hour period (see Fig. 1, all p < 0.01). This result indi-
cates that the biomarkers that we chose to measure were
elevated in response to surgical stress, and that the time
course of cytokine response was adequately captured
with our sampling method.
With the exception of CRP, there was no group versus
time difference in inflammatory biomarker levels between
the control and intervention groups (see Fig. 1).
Discussion
Our study, like many others, demonstrated that the
utilization of GDT in patients undergoing high-risk
surgery results in an increased CI and SVI when
compared to controls. This increase in CI was due to an
increase in the amount of colloid administered in the
intervention group. This increase in CI was also associated
with a decrease in postoperative complications. Despite
this increase in CI and decrease in postoperative compli-
cations, GDT was not associated with a decreased LOS
nor a reduction in the level of inflammatory biomarkers
(with the exception of CRP). Our hypothesis was that the
improved CI seen in GDT patients was due to improved
resuscitation of the endothelium and would be manifest
by decreases in inflammatory biomarkers.
The lack of a difference in LOS could be due to many
factors not related to the hemodynamic improvements
seen in our intervention group. For example, patients
Table 2 Intra-operative and post-operative data
Control group n = 20 Intervention group n = 20 p
Intra-operative data
Surgery duration (minutes) 228 (210–243) 210 (175–246) 0.40
Aortic cross clamp time (minutes) 50 (38–69) 52 (40–64) 0.93
Vasopressors 15 19 0.08
Estimated blood loss (ml) 725 (462–1,188) 925 (500–1,425) 0.53
Crystalloid (ml) 2,050 (1,200–2,650) 1,650 (1,050–2,088) 0.03
Colloid (ml) 500 (500–675) 1,000 (750–1,250) <0.001
Urine output (ml) 226 (178–322) 195 (94–315) 0.29
Post-operative data
Total crystalloid (l) 13.4 ± 6.8 11.8 ± 4.4 0.79
Total colloid (ml) 595 ± 366 1,298 ± 667 <0.001
Enteral nutrition (days) 3 (2–4) 3 (2–4) 0.44
Full diet (days) 5 (4–7) 4 (3–6) 0.43
Hospital LOS (days) 8 (6–12) 8 (7–13) 0.73
Patients in the intervention group received significantly more colloid and less crystalloid than those in the control group. Values for fluids, operative, aortic cross
clamp times, enteral nutrition, full diet and hospital length of stay are shown as median (interquartile range). Other values are shown as mean ± SD. LOS length
of stay
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discharge from hospital. Fitness for discharge is likely a
better parameter to examine in this situation.
We chose a broad panel of both pro- and inflammatory







Beginning of study 76 ± 8 78.2 ± 11 0.50
End of study 78 ± 11 79.6 ± 7 0.63
HR (bpm)
Beginning of study 58 ± 10 63 ± 9 0.12
End of study 67 ± 10 69 ± 11 0.65
CVP (mmHg)
Beginning of study 9.3 ± 3 10.4 ± 5 0.48
End of study 10.3 ± 4 11.1 ± 3 0.58
CI (l/minute per m2)
Beginning of study 2.5 ± 0.4 2.5 ± 0.3 0.94
End of study 2.5 ± 0.7 3.4 ± 0.5 <0.0001
SVV
Beginning of study 10.0 ± 5 9.6 ± 2 0.79
End of study 12.1 ± 5 5.6 ± 2 <0.001
SVI (ml/m2)
Beginning of study 43 ± 8 40 ± 6 0.29
End of study 38 ± 9 50 ± 7 <0.001
CI cardiac index, CVP central venous pressure, HR heart rate, MAP mean arterial
pressure, SVI stroke volume index, SVV stroke volume variationmedical stress to determine if GDT resulted in a di-
minished perioperative inflammatory response. The surgi-
cal stimulus resulted in a significant inflammatory response
as demonstrated by the fact that cytokines measured at the
immediate postoperative time period were significantly
greater than baseline (all p < 0.05, data not shown).
Renal cells in response to inflammatory stimuli secrete
MCP-1, and MCP-1 levels are elevated in glomeruloneph-
ritis and diabetic nephropathy [26, 27]. MCP-1 is also ele-
vated in patients with atherosclerotic disease [28, 29].
PTX3 is part of the humoral arm of innate immunity, and
is in the same family as CRP. Increased levels of PTX3
have been seen in ischemia-reperfusion injury as well as
patients with septic shock and acute kidney injury.
Traditional fluid administration to patients presenting
for high-risk surgery relied on the use of static parameters
such as CVP, MAP, and urine output. There are several
studies that have shown that using these parameters to
gauge fluid administration leaves patients effectively hypo-
volemic with decreased CI [8, 10, 11, 30]. This decrease in
CI has been shown to be associated with gut mucosal
hypoperfusion and this may lead to an increase in the
inflammatory response seen after surgery [31–33].
There are few papers that have studied the inflammatory
response to GDT. Noblett et al. [9] randomized patients
undergoing elective colonic resection to GDT or control
using esophageal Doppler as their cardiac output monitor.
Similar to our study, they demonstrated an increase in CI
in the intervention group and a reduced incidence of
complications in the postoperative period. They measured
IL-6 levels at similar time points to our study and found
that the peak IL-6 levels (at the 6-hour time point) were






Myocardial infarction 3 1
Pneumonia 1 1
Respiratory failure 1 0
Sepsis 1 0
Rhabdomyolysis 1 0
Acute kidney injury 4 4
Dysrhythmia 3 2
Bleeding 2 1
Ischemic gut 1 0
Delirium 3 2
ICU admission 6 1
Death 2 0
Total 28 12 0.02
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that there was less inflammation in their GDT group [9].
Measured at the same time point (6 hours postoperatively),
the levels of IL-6 in our study (81 ± 144 pg/ml) were lower
than those of Noblett (369 pg/ml). It is unclear why a dif-
ference was demonstrated in their study and not ours, and
why the levels of cytokines were almost fivefold higher in
their study. Differences in assay techniques and sensitivity
could explain the differences between our studies.
In a mouse endotoxin model, levels of tumor necrosis
factor (TNF)-α were lower in animals given dopexamine
to improve global blood flow when compared with con-
trols [15]. This decrease in TNF-α in the dopexamine
group occurred despite similar SVI.
Jhanji et al. also looked at inflammatory biomarkers in a
GDT trial in gastrointestinal surgery patients [16]. They
demonstrated increased oxygen delivery and improved
sublingual and cutaneous microvascular flow in patients
treated with stroke volume optimization and dopexamine
administration. They also found no difference in inflamma-
tory biomarkers (IL-6, IL-8, IL-1β, TNF-α, and ICAM-1)
between the dopexamine-treated group and a control
group who had their fluids titrated based on CVP alone.
The only other paper that examined the inflammatory
response to GDT was from Rivers et al. [34]. In this study,
Rivers looked at the cytokine response in patients from
his seminal paper on GDT for septic shock [35]. In this
study he found that the levels of IL1-Ra, TNF and IL-6
were higher in the patients that underwent GDT for
their septic shock. This therapy included the aggressive
administration of fluids, vasopressors, red blood cell trans-
fusion and treatment with inotropes. Levels of cytokines
in this study were approximately 10-fold higher than in
our study, indicating a much higher inflammatory burden
in these critically ill patients.It is difficult to compare our results with those in the
Rivers study as his patients had an ongoing stimulus for
the inflammatory response (their ongoing infection that
caused the septic shock), whereas at the end of surgery
the inflammatory response in our patients was removed.
Our results are, however, consistent with those of
Jhanji et al. looking at the role of the inflammatory
response to GDT [16].
Furthermore, it is difficult to examine only one cytokine
and make broad comments about the overall inflammatory
response. The human immune system is pleiotropic and
redundant and there is abundant cross regulation between
the pro- and anti-inflammatory arms. We measured cyto-
kines from both the pro- and anti-inflammatory arms, and
therefore can make more robust conclusions about the
overall inflammatory burden that our patients underwent.
How then do we explain the fact that patients in our
GDT group had improved CI and fewer complications
yet suffered a similar inflammatory burden? It is known
that endothelial integrity is maintained via proteins that
intercalate between cells. Endothelial cells are tightly bound
together by a protein called VE-cadherin. VE-cadherin is
present on the surface of endothelial cells and is responsible
for preventing interstitial edema. Cytokines and other
inflammatory mediators are known to disrupt these
proteins, leading to increased endothelial permeability,
tissue edema, cellular hypoxia and organ dysfunction
[19]. Expression of the Slit protein and its cognate receptor
Robo have been shown to stabilize VE-cadherin protein
binding between cells, thus reducing endothelial permeabil-
ity [36]. Interestingly, in animal models of acute respiratory
distress syndrome, septic shock, and infection with avian
influenza virus, pretreatment with Slit protein reduced
disease mortality in infected animals, but did not reduce
cytokine levels [37]. This suggests that vascular integrity
was maintained, despite a similar inflammatory response.
A similar phenomenon could have occurred in our
patients; that is, despite a similar inflammatory stress
in both groups of patients (which would be expected
as they underwent identical procedures), endothelial
integrity was maintained in the GDT group, and this
resulted in less tissue hypoxia and organ dysfunction.
Our results suggest that the improved postoperative
outcomes seen in GDT are not related to differences
in the inflammatory response, and thus must result from a
different mechanism.
Therefore, an alternative way of interpreting our re-
sults would be to conclude that, despite a similar inflam-
matory burden, patients in the GDT group had fewer
complications.
The earliest studies of GDT examined the concept of
oxygen debt in the critically ill and high-risk surgical
patients [38, 39]. These studies found patients that
presented to the emergency department with shock
Fig. 1 Cytokine levels over time. a Interleukin-6 (Il-6); b interleukin-10 (IL-10); c interleukin-1-receptor antagonist (IL1-Ra); d macrophage
chemotactic protein-1 (MCP-1); e Pentraxin 3 (PTX3); f suppressor of tumorgenicity-2 (also known as interleukin receptor-1-like 1) (ST-2);
g tumor necrosis factor receptor type II (TNF-RII); h C-reactive protein (CRP). There was no difference between the control and intervention groups
(group versus time interaction, repeated measures analysis of variance, all p > 0.05)
Funk et al. Critical Care  (2015) 19:247 Page 7 of 9had lower oxygen delivery indices than those who sur-
vived their shock state. These early observations led to the
concept of an oxygen debt that patients incur when
undergoing high-risk surgery or when they are criticallyill. This oxygen debt leads to tissue hypoperfusion and
organ system dysfunction. Subsequent studies utilized an
oxygen delivery-based protocol for fluid, blood product
and inotrope administration to try and maximize oxygen
Funk et al. Critical Care  (2015) 19:247 Page 8 of 9delivery. Some of these studies found that targeting an
increased oxygen delivery resulted in lower mortality and
fewer complications [40–42]. Subsequent trials were
unable to confirm these results [43–45]. Unfortunately,
we did not measure oxygen consumption in our patients,
so we cannot be sure if our control group incurred an
oxygen debt. However, despite the differences in CI
between groups at the end of the study, oxygen delivery
was not significantly different between groups, thus
lessening the likelihood that a significant oxygen debt
played a role in the increased complication rate in
the control patients.
Limitations to our study include the small size, and the
inability to measure CI in the postoperative period. Further,
due to logistical complications, we only measured cytokine
levels to 24 hours, and there may have been a difference
after this time point. However, in our pilot trial, we mea-
sured cytokine levels at 48 hours and at this time point the
levels were returning to baseline. Utilizing a SVV target of
13 % has also recently come under question as being in a
‘grey zone’ of fluid responsiveness [46]. Despite this, we did
demonstrate an increase in CI in our intervention group.
We also did not measure lactate in the postoperative
period, which would potentially have informed us if an
oxygen debt or tissue hypoperfusion were occurring.
Future studies should focus on alternative explanations
for the underlying mechanism as to why patients in
the intervention arm of GDT trials have reduced
complications.
Conclusion
Our study demonstrated that GDT in patients under-
going open repair of their AAA was not associated
with a reduction in the inflammatory response. Future
studies on the mechanism of benefit of GDT should focus
on mechanisms other than alterations in the inflammatory
response.
Key messages
 GDT in high-risk vascular patients results in
improved CI/SVI.
 This improvement in hemodynamics resulted in
decreased complications.
 These improved outcomes occurred despite a similar
magnitude in the inflammatory response to surgery.
 Future trials examining the mechanism of benefit of
GDT should focus on pathways other than the
inflammatory response.
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